Windtree Therapeutics Inc Stock Price, News & Analysis

Windtree Therapeutics (NASDAQ:WINT) has announced positive interim analysis results from its SEISMiC C Phase 2 study evaluating istaroxime in SCAI Stage C cardiogenic shock patients. The study demonstrated that istaroxime maintained its safety profile and showed consistent physiological improvements when combined with current standard treatments.

The global, placebo-controlled, double-blinded trial included sites across the U.S., Europe, and Latin America, building upon previous successful SEISMIC B study results. The interim analysis of the first 20 patients revealed no new safety concerns or excess arrhythmias when istaroxime was administered alongside standard therapies. The company plans to advance to a global Phase 3 trial based on these encouraging results.

Windtree Therapeutics (NASDAQ:WINT) has announced significant reductions in its preferred stock shares outstanding through conversion and redemption. The company achieved a 99.3% reduction in Series C Preferred Stock to just 19 shares and a 68.5% reduction in Series D Preferred Stock to 1,161 shares between April 15 and July 25, 2025.

The announcement comes alongside updates on Windtree's crypto treasury strategy, including a $60 million investment agreement with Build and Build Corp, with potential follow-on subscriptions of up to $140 million. The company has also secured commitments for up to $700 million for BNB acquisitions. Notably, BNB coin has appreciated by over 17% since the initial announcement of the crypto treasury agreement.

Investors redeemed approximately $2.3 million worth of preferred series C and D shares, which could have been converted into approximately 7.7 common shares, effectively limiting future dilution.

Windtree Therapeutics (NASDAQ:WINT) has secured up to $520 million in new funding to expand its BNB cryptocurrency treasury strategy. The funding consists of a $500 million equity line of credit (ELOC) and a $20 million stock purchase agreement with Build and Build Corp.

The company plans to allocate 99% of the proceeds from both agreements to acquiring BNB cryptocurrency. The ELOC implementation is contingent on stockholder approval to increase authorized shares of common stock. This strategic move represents Windtree's effort to diversify its treasury assets through blockchain-based digital currencies.

Windtree Therapeutics (NASDAQ:WINT) has announced a strategic partnership with Kraken, a major cryptocurrency platform, to provide custody, trading, and OTC services for Windtree's BNB Crypto Treasury Strategy. The partnership is contingent on shareholder approval of a previously announced securities purchase agreement that could bring up to $140 million in future subscriptions.

As the first NASDAQ-listed company offering direct exposure to the BNB token, which has a market cap exceeding $100 billion, Windtree will leverage Kraken's security infrastructure and expertise to manage digital assets and facilitate large-scale transactions. The Binance Smart Chain ecosystem, which BNB supports, processes over $2 billion in average daily trading volumes and hosts thousands of decentralized applications.

Windtree Therapeutics (NASDAQ:WINT) has announced a significant strategic shift with a $60 million securities purchase agreement led by Build and Build Corp, with potential additional subscriptions of up to $140 million. The company aims to become the first NASDAQ-listed entity offering direct exposure to the BNB token, the fifth-largest blockchain by market capitalization (over $95 billion).

The proceeds will primarily fund a BNB crypto treasury strategy, positioning Windtree as a pioneer in the Binance ecosystem. The transaction, subject to shareholder approval, will establish a comprehensive strategy including custody, security, and yield generation. BNB currently maintains average daily trading volumes exceeding $2 billion, making it the largest crypto exchange token globally.

Windtree Therapeutics (NASDAQ:WINT) has secured a new U.S. patent for istaroxime, its drug candidate for treating acute heart failure (AHF). The patent (application #18/150,870) covers istaroxime-containing intravenous formulation and extends protection until 2039.

The drug has already demonstrated success in two Phase 2 AHF studies and two early cardiogenic shock studies. This development is particularly significant as AHF affects 1.3 million hospitalized patients annually in the U.S. and represents the leading cause of hospitalization for patients over 65 years old.

Windtree Therapeutics (NASDAQ:WINT) has achieved its target enrollment of 20 patients for the interim analysis of its Phase 2 SEISMiC C study, evaluating istaroxime in SCAI Stage C cardiogenic shock patients. The study represents the third trial in the company's istaroxime cardiogenic shock development program, following two previously successful Phase 2 studies in SCAI Stage B patients.

The SEISMiC C trial is a global, placebo-controlled, double-blinded study conducted across the U.S., Europe, and Latin America. The study evaluates istaroxime in combination with standard care treatments, including inotropes and vasopressors. The primary endpoint focuses on systolic blood pressure profile during the first six hours of treatment.

The interim analysis will primarily assess preliminary safety, tolerability, and efficacy signals to determine appropriate sizing for the remainder of the trial. The company notes that a statistically significant efficacy signal is not expected at this interim stage. The data from this study will be crucial for Phase 3 readiness and upcoming FDA discussions.

Windtree Therapeutics (NASDAQ:WINT) has secured a contract with a Chinese pharmaceutical manufacturer to produce PHEXXI, Evofem's hormone-free contraceptive gel, at significantly reduced costs. The manufacturing agreement is expected to cut PHEXXI production costs by over 50% by the end of 2026.

The technology transfer process has begun, with early-stage manufacturing scheduled to start later in 2025. This arrangement, stemming from Windtree's March 2025 License and Supply Agreement with Evofem, is anticipated to generate revenue for Windtree starting in 2026. PHEXXI has shown four consecutive years of net sales growth, with plans for international expansion beginning with a marketing approval submission in the UAE.

Windtree Therapeutics (WINT) announced the publication of positive Phase 2 SEISMiC B study results for istaroxime in the Journal of Heart and Lung Transplantation. The study demonstrated significant efficacy in treating early cardiogenic shock, with istaroxime increasing blood pressure over 6 hours and maintaining effects for 60 hours. Key benefits included improved cardiac output, decreased pulmonary capillary wedge pressure, no increase in heart rate, no significant arrhythmias, and preserved renal function. The company is in partnership discussions to fund remaining clinical development, targeting the $1.25 billion cardiogenic shock market. Windtree plans to release interim data from the SEISMiC C trial in July and is finalizing Phase 3 protocol design for acute heart failure indication in China with a regional partner.